Psychological Monitoring for Obesity Medications
HealthRX.com
Ask about mood changes before and during obesity treatment
Key numbers
- HR 0.27Hazard ratio for new suicidal ideation with semaglutide versus non-GLP-1 anti-obesity medicationSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- OR 1.55Odds ratio for later depression after obesity at baseline in pooled longitudinal studiesSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 1.4%Median lifetime prevalence of binge eating disorder in community surveys of adultsSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- GLP-1 labels / Saxenda, Wegovy and Zepbound no longer carry the suicidal ideation warning [2][3][4]
- Contrave / Boxed warning for suicidal thoughts and behaviors [5]
- Qsymia / Suicidal behavior and ideation warning retained; REMS for fetal harm [6]
- Depression screen / PHQ-9 score of 10 or higher: 88% sensitivity, 88% specificity in 580 interviewed patients [8]
- Bidirectional risk / Obesity OR 1.55 for depression onset; depression OR 1.58 for obesity onset [7]
- Binge eating disorder / Median lifetime prevalence 1.4% across 14 countries [9]
- Anxiety / Pooled OR 1.4, cross-sectional data only [10]
- Doctor bias / Mean implicit anti-fat bias among 2,284 physicians, Cohen d 0.93 [11]
What does the FDA say about GLP-1 drugs and suicidal thoughts?
FDA opened its review in July 2023, after postmarketing reports of suicidal ideation and behavior in people taking GLP-1 receptor agonists, and published a preliminary review of trial and postmarketing data in January 2024 [1]. After a comprehensive review it found no increased risk and, on 13 January 2026, asked manufacturers to remove the warning language from the labeling of Saxenda, Wegovy and Zepbound [1]. The current Saxenda, Wegovy and Zepbound labels no longer carry it [2][3][4].
Labeling for GLP-1 medicines approved for diabetes indications does not currently include information about suicidal ideation or behavior [1].
Dr Josef Witt-Doerring on why the FDA's GLP-1 mood finding is wrong
Dr. Josef Witt-Doerring argues that the FDA's finding of no increased suicidal risk with GLP-1 drugs is flawed. In his view, large placebo-controlled trials can hide real harm when a drug improves some people's mood through weight loss while harming others, and case reports from clinicians should count as evidence. He worries that telling doctors to refer patients with mood symptoms to psychiatry could delay recognizing the drug as the cause. He suggests that people who develop worsening anxiety or depression soon after starting these drugs should suspect the medication and talk to their doctor, and that symptoms often ease after stopping.
Who is speaking?
Dr. Josef Witt-Doerring. Board-certified psychiatrist and former FDA medical officer, as described on the channel and in the video Background
Which obesity drugs still carry psychiatric warnings?
Contrave (naltrexone/bupropion extended-release) carries a boxed warning for suicidal thoughts and behaviors, the antidepressant class warning that covers children, adolescents and young adults [5][1]. Its contraindications include bulimia or anorexia nervosa, seizure disorder, uncontrolled hypertension, chronic opioid use, other bupropion products, and MAO inhibitors within 14 days [5].
Qsymia (phentermine/topiramate extended-release) retains a suicidal behavior and ideation warning, attributed to topiramate [6][1]. Qsymia can cause fetal harm and is contraindicated during pregnancy, and in people with glaucoma or hyperthyroidism or who use an MAO inhibitor or have used one within 14 days [6]. The label recommends a negative pregnancy test before starting and monthly during treatment, and the drug is dispensed only through certified pharmacies under a REMS [6].
How closely are obesity and depression linked?
Luppino and colleagues pooled 15 longitudinal studies with 58,745 participants. Obesity at baseline raised the odds of depression at follow-up (OR 1.55, 95% CI 1.22 to 1.98), and depression at baseline raised the odds of later obesity (OR 1.58, 95% CI 1.33 to 1.87) [7]. Those odds ratios were unadjusted. The obesity-to-depression association was stronger for clinically diagnosed depression than for depressive symptoms, and stronger among Americans than among Europeans. Overweight, BMI 25 to under 30, carried a smaller increase (OR 1.27), and baseline depression did not predict later overweight [7].
Anxiety shows a similar but weaker pattern. A systematic review found 16 studies, 2 prospective and 14 cross-sectional, with a pooled odds ratio of 1.4 (95% CI 1.2 to 1.6) from the cross-sectional data. The prospective results were mixed, and the authors concluded that a causal direction could not be inferred [10].
How common is binge eating disorder alongside obesity?
In community surveys of 24,124 adults across 14 countries, the median lifetime prevalence of binge eating disorder was 1.4% (interquartile range 0.8 to 1.9), and fewer than half of lifetime cases received any treatment [9]. Among 404 patients with the disorder, 73.8% had at least one other lifetime psychiatric diagnosis and 43.1% had at least one current one; current comorbidity went with more severe eating-disorder psychopathology and more distress [12].
Which screening tool has been validated?
Of 6,000 primary care and obstetrics-gynecology patients who completed the PHQ-9, 580 had a structured mental health professional interview. In that interviewed group, a score of 10 or higher had 88% sensitivity and 88% specificity for major depression, and scores of 5, 10, 15 and 20 marked mild, moderate, moderately severe and severe depression [8]. The study population was general primary care and gynecology patients, not people selected for obesity.
Do GLP-1 drugs change mood outcomes?
A retrospective cohort using US electronic health records followed 240,618 patients with overweight or obesity who were prescribed semaglutide or a non-GLP-1 anti-obesity medication, matched by propensity score, over six months. Semaglutide was associated with a lower risk of incident suicidal ideation (HR 0.27) and of recurrent suicidal ideation (HR 0.44, 95% CI 0.32 to 0.60), and the findings replicated in 1,589,855 patients with type 2 diabetes [16]. The design cannot establish causation, and the authors concluded only that their findings did not support a higher risk with semaglutide [16].
WHO recommends GLP-1 therapies for long-term treatment of obesity in adults as a conditional recommendation, weighing limited long-term data, cost and health-system readiness [18]. Its safety committee described a well-established positive benefit-risk profile when the drugs are used as approved under professional supervision, and warned about use outside the approved indication and about unregulated or falsified products [19].
What people on Reddit report
Reddit posts and replies from people taking Ozempic (semaglutide) who describe their mood, depression or anhedonia during treatment. Experiences are mixed and disagree with each other.
I've found it helps my mental health. I just feel more positive overall. I was actually surprised when I realized I feel "better" mentally.Read the source discussion
But I would say that you are right to wonder if the ozempic might make it worse. It's a healthy consideration. If you decide to go with it, make sure you draw some lines in the sand.Read the source discussion
But to me it was real, and it was serious. And I am having a very hard time at a low dose now as it does not quite quiets the food noise as it used to.Read the source discussion
Questions worth asking
What role does weight stigma play?
Weight stigma is a psychosocial contributor to obesogenic behaviors, linked in the literature to maladaptive eating, lower physical activity and stress [20]. In young people it takes the form of victimization by peers, parents and teachers, and is associated with depressive symptoms, low self-esteem and suicidal ideation [21].
Physicians are not exempt. Of 2,284 doctors who completed a weight implicit association test, the average implicit anti-fat bias was strong, with a Cohen d of 0.93, and strong explicit anti-fat preference was also reported; the authors described implicit and explicit anti-fat bias as pervasive among doctors as among the general public [11].
Which psychiatric medications add weight?
A synthesis of 81 articles estimated weight change after 10 weeks at standard doses: clozapine plus 4.45 kg, olanzapine plus 4.15 kg, risperidone plus 2.10 kg, ziprasidone plus 0.04 kg, against minus 0.74 kg with placebo. There were insufficient data to evaluate quetiapine at 10 weeks [22]. A separate review found antipsychotics, and to a lesser degree antidepressants and mood stabilizers, associated with increased risk of obesity, dyslipidemia, diabetes and other physical diseases [23].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Do GLP-1 weight-loss drugs raise suicide risk?
Which obesity drugs still carry mental-health warnings?
How strong is the link between obesity and depression?
What is the PHQ-9 and how accurate is it?
How common is binge eating disorder in people with obesity?
Which antipsychotics cause the most weight gain?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What mental disorders are linked to obesity?
Obesity is linked to depression, anxiety and binge eating disorder. Obesity raised the odds of later depression (OR 1.55), anxiety showed a similar but weaker pattern (pooled OR 1.4), and binge eating disorder had a median lifetime prevalence of 1.4% across 14 countries.
Does obesity cause depression and anxiety?
The studies do not establish causation. Obesity at baseline was associated with higher odds of later depression (OR 1.55), but those odds ratios were unadjusted. For anxiety, the prospective results were mixed, and the authors concluded that a causal direction could not be inferred.
References
Show all 25 referencesHide references
- FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications | FDA.
- U.S. National Library of Medicine, DailyMed. Saxenda injection (liraglutide) prescribing information. Saxenda injection (liraglutide) label
- U.S. National Library of Medicine, DailyMed. Wegovy injection and tablets prescribing information. Wegovy injection and tablets label
- U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
- U.S. National Library of Medicine, DailyMed. Contrave extended-release tablets (naltrexone hydrochloride and bupropion hydrochloride) prescribing information. Contrave extended-release tablets (naltrexone hydrochloride and bupropion hydrochloride) label
- U.S. National Library of Medicine, DailyMed. Qsymia capsules (phentermine and topiramate) prescribing information. Qsymia capsules (phentermine and topiramate) label
- Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-9.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-13.
- Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, Shahly V, et al. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013;73(9):904-14.
- Gariepy G, Nitka D, Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis. Int J Obes (Lond). 2010;34(3):407-19.
- Sabin JA, Marini M, Nosek BA. Implicit and explicit anti-fat bias among a large sample of medical doctors by BMI, race/ethnicity and gender. PLoS One. 2012;7(11):e48448.
- Grilo CM, White MA, Masheb RM. DSM-IV psychiatric disorder comorbidity and its correlates in binge eating disorder. Int J Eat Disord. 2009;42(3):228-34.
- McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiatry. 2015;72(3):235-46.
- US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(11):1163-1171.
- US Preventive Services Task Force, Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR, et al. Interventions for High Body Mass Index in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;332(3):226-232.
- Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168-176.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232.
- WHO issues global guideline on the use of GLP-1 medicines in treating obesity.
- Statement from the Joint Meeting of the Advisory Committee on Safety of Medicinal Products (ACSoMP) and the Global Advisory Committee on Vaccine Safety (GACVS) on the safe and appropriate use of GLP‑1 receptor agonists.
- Puhl RM, Himmelstein MS, Pearl RL. Weight stigma as a psychosocial contributor to obesity. Am Psychol. 2020;75(2):274-289.
- Puhl RM, Lessard LM. Weight Stigma in Youth: Prevalence, Consequences, and Considerations for Clinical Practice. Curr Obes Rep. 2020;9(4):402-411.
- Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.
- Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-36.
- Reddit participants. Ozempic at Bmi 25, depression/mental health (r/Ozempic). Accessed 2026-11-10.
- Dr. Josef. Ozempic Mental Health Effects, Explained for Beginners. Accessed 2026-11-10.